STOCKS TELEGRAPH

Tag: electroCore

  • electroCore Inc. (ECOR) Stock on the Rise Following Announcement of Newly Issued Patent

    electroCore Inc. (ECOR) stock prices were up 3.92% as of the market closing on July 27th, 2021, bringing the price per share up to USD$0.9665 at the end of the trading day. Subsequent premarket fluctuations saw the stock rise by 5.54%, bringing it up to USD$1.02.

    ECOR Stock’s Patent

    July 27th, 2021 announced that the United States Patent and Trademark Office (USPTO) has granted ECOR stock U.S. Patent No. 11,065,444. The patent issued to the commercial-stage bioelectronic medicine company is in regard to the use of a mobile phone for the stimulation of the trigeminal nerve to treat disorders. The new patent is owned by the company and is the most recent U.S patent to be issued in connection with the company’s development of non-invasive solution programs for pain.

    Patented Technology

    The newly issued patent includes descriptions of devices and methods that can be used by patients themselves to treat medical conditions, such as migraine headaches, with non-invasive means. ECOR stock achieves this by the electrical stimulation of nerves in the head, particularly supraorbital, supratrochlear, infraorbital, and mental nerves in the general area of patients’ foramen or notch.

    About the Treatment

    The system consists of a handheld mobile device, like a smartphone, that is applied to the surface of the head of the patient being treated. Electrical impulses are applied through the patient’s skin via one or more electrodes, serving to modulate a targeted nerve to treat the medical condition. ECOR stock’s system aims to provide patients with a self-treatment solution in the absence of a medical professional.

    Expansive Scope of Treatment

    ECOR stock is keen to continue the advancement of its non-invasive treatment solutions for its patients. The new development massively increases the scope of the reach and accessibility by which the company’s therapy may be deployed. This facilitates more patients all over the world to get the relief they need while not having to leave the comfort of their homes. This is line with the company’s vision of improving patient outcomes with its nerve stimulation therapy platform, which initially focused on the treatment of various neurological conditions.

    Future Outlook for ECOR Stock

    Armed with the security of the patenting of its proprietary technology, ECOR stock is poised to capitalize on the opportunities and tenure afforded to it over the long term. The company is keen to spearhead market penetration in an effort to usher in significant and sustained increases in shareholder growth.

  • Why shares of electroCore Inc. (ECOR) stock are popping high in Pre-Market?

    Why shares of electroCore Inc. (ECOR) stock are popping high in Pre-Market?

    Shares of electroCore Inc. (ECOR), a medical technology company, are popping high in pre-market on the 1st day of March 2021. As of 5:40 AM EST, the share price reached $3.51 recording a gain of 61.75%. Let’s deep dive to understand the reason behind this bull.

    What’s Happening?

    Company on February 28, 2021, announced that it has signed an agreement with Medistar2 PTY Limited. According to the agreement, Medistar will now serve as the exclusive distributor of thegammaCore Sapphire non-invasive vagus nerve stimulator (nVNS) in Australia. The core purpose is to cure primary headache disorders by supplying therapy to patients. The announcement was made after getting approval from the Australian Therapeutic Goods Administration (TGA) to promote and sell the gammaCore Sapphire family of products.

    The agreement is valid for the next three years and contains specific customary terms and conditions which also include minimum purchase requirements. Medistar will launch gammaCore Sapphire at the 2021 ANZHS Headache Annual Scientific Two-day Meeting oncoming March 13-14. 

    GammaCore Sapphire is a drug-free device, and it has no side effects. Furthermore, it will also help to explore interfacing with the vagus nerve and the anti-inflammatory pathway.

    Conclusion:

    Investors are taking interest in the ECOR stock after its agreement with Medistar2 PTY Limited. The company has a good future in the upcoming days as it looks like the ECOR will produce a massive profit by selling its headache relief device in Australia.